{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:56:35Z","timestamp":1793040995895,"version":"4.5.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Tildrakizumab, the IL-23 inhibitor, is used to treat plaque psoriasis and psoriatic arthritis. Many studies have reported adverse drug reactions (ADRs) associated with Tildrakizumab.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> The aim of this study was to describe ADRs associated with Tildrakizumab monotherapy by mining data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The signals of Tildrakizumab-associated ADRs were quantified using disproportionality analyses such as the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multiitem gamma Poisson shrinker (MGPS) algorithms.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 10,530,937 reports of ADRs were collected from the FAERS database, of which 1,177 reports were identified with tildrakizumab as the \u201cprimary suspect (PS)\u201d. Tildrakizumab-induced ADRs occurred against 27 system organ classes (SOCs). A total of 32 significant disproportionality Preferred Terms (PTs) conformed to the algorithms. Unexpected significant ADRs such as coronavirus infection, herpes simplex, diverticulitis, atrial fibrillation and aortic valve incompetence were also possible. The median time to onset of Tildrakizumab-associated ADRs was 194 days (interquartile range [IQR] 84\u2013329 days), with the majority occurring, within the first 1 and 3 months after initiation of Tildrakizumab.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This study identified a potential signal for new ADRs with Tildrakizumab, which might provide important support for clinical monitoring and risk prediction.<\/jats:p>","DOI":"10.3389\/fphar.2024.1420478","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T12:50:59Z","timestamp":1720615859000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018\u20132023"],"prefix":"10.3389","volume":"15","author":[{"given":"Jinger","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwei","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haosong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqian","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"B2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1177\/12034754231155889","article-title":"Tildrakizumab in complex psoriatic patients: an experience in emilia-romagna (Italy)","volume":"27","author":"Bardazzi","year":"2023","journal-title":"J. Cutan. Med. Surg."},{"key":"B3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40199-024-00508-z","article-title":"Educational interventions in pharmacovigilance to improve the knowledge, attitude and the report of adverse drug reactions in healthcare professionals: systematic Review and Meta-analysis","volume":"32","author":"Cervantes-Arellano","year":"2024","journal-title":"Daru"},{"key":"B4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/bf03256733","article-title":"Comparison of sensitivity and timing of early signal detection of four frequently used signal detection methods","volume":"22","author":"Chen","year":"2008","journal-title":"Pharm. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1111\/jdv.19229","article-title":"Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice","volume":"37","author":"Costanzo","year":"2023","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/pds.4970","article-title":"Adverse drug reaction or innocent bystander? A systematic comparison of statistical discovery methods for spontaneous reporting systems","volume":"29","author":"Dijkstra","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/14712598.2018.1504016","article-title":"An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly","volume":"18","author":"Di Lernia","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2220447","DOI":"10.1080\/09546634.2023.2220447","article-title":"Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest","volume":"34","author":"Egeberg","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1101861","DOI":"10.3389\/fphar.2023.1101861","article-title":"A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system","volume":"14","author":"Fang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1111\/ijd.15840","article-title":"Tildrakizumab: short-term efficacy and safety in real clinical practice","volume":"61","author":"Gal\u00e1n-Gutierrez","year":"2022","journal-title":"Int. J. Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/14712598.2022.1988566","article-title":"Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations","volume":"22","author":"Galluzzo","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"B12","volume-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","year":"2021"},{"key":"B13","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1111\/jdv.15643","article-title":"Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: letter to the Editor","volume":"33","author":"Gooderham","year":"2019","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/bjd.18897","article-title":"Outcomes of pregnancies from the tildrakizumab phase I-III clinical development programme","volume":"183","author":"Haycraft","year":"2020","journal-title":"Br. J. Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4103\/0019-5154.182416","article-title":"Biostatistics series module 3: comparing groups: numerical variables","volume":"61","author":"Hazra","year":"2016","journal-title":"Indian J. Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/ph15010027","article-title":"Analysis of factors associated with hiccups using the FAERS database","volume":"15","author":"Hosoya","year":"2021","journal-title":"Pharm. (Basel)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","article-title":"Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents","volume":"80","author":"Kaushik","year":"2019","journal-title":"J. Am. Acad. Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/bjd.18484","article-title":"Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies","volume":"182","author":"Kimball","year":"2020","journal-title":"Br. J. Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/14740338.2019.1614561","article-title":"A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data","volume":"18","author":"Kolli","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jaad.2020.09.047","article-title":"Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)","volume":"84","author":"Lebwohl","year":"2021","journal-title":"J. Am. Acad. Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/cpt.3139","article-title":"Drug-induced acute pancreatitis: a real-world pharmacovigilance study using the FDA adverse event reporting system database","volume":"115","author":"Li","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/14712598.2019.1561850","article-title":"Anti-interleukin-12 and anti-interleukin-23 agents in Crohn\u2019s disease","volume":"19","author":"Macaluso","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40265-018-0917-3","article-title":"Tildrakizumab: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/bjd.17625","article-title":"Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review","volume":"181","author":"Mason","year":"2019","journal-title":"Br. J. Dermatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e15818","DOI":"10.1111\/dth.15818","article-title":"Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement","volume":"35","author":"Mastorino","year":"2022","journal-title":"Dermatol Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/jdv.18594","article-title":"Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis)","volume":"37","author":"Narcisi","year":"2023","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief. Bioinform"},{"key":"B30","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41584-021-00646-7","article-title":"Tildrakizumab shows promise in phase IIb study","volume":"17","author":"Onuora","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.5114\/amsad.2016.64165","article-title":"Assessment of subclinical cardiac damage in chronic plaque psoriasis patients: a case control study","volume":"1","author":"Ozden","year":"2016","journal-title":"Arch. Med. Sci. Atheroscler. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"985646","DOI":"10.1155\/2012\/985646","article-title":"IgG placental transfer in healthy and pathological pregnancies","volume":"2012","author":"Palmeira","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/jdv.15400","article-title":"Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28","volume":"33","author":"Papp","year":"2019","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B34","unstructured":"Sun pharma announces U.S. FDA approval of ILUMYATM (tildrakizumab-asmn) for the treatment of moderate-to-severe plaque psoriasis\n            PharmaS.\n          2022"},{"key":"B52","unstructured":"A practical and systematic review of Weibull statistics for reporting strengths of dental materials, Dent. Mater135147\n            QuinnJ. B.\n            QuinnG. D.\n          10.1016\/j.dental.2009.09.006262010"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1016\/j.apsb.2021.05.028","article-title":"Hepatotoxicity reports in the FDA adverse event reporting system database: a comparison of drugs that cause injury via mitochondrial or other mechanisms","volume":"11","author":"Rana","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"B36","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"Br. J. Dermatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00281-019-00742-7","article-title":"T cell pathology in skin inflammation","volume":"41","author":"Sabat","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7150\/ijms.7967","article-title":"Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms","volume":"11","author":"Sakaeda","year":"2014","journal-title":"Int. J. Med. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"104476","DOI":"10.1016\/j.yrtph.2019.104476","article-title":"Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates","volume":"108","author":"Santostefano","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"CD011535","DOI":"10.1002\/14651858.CD011535.pub5","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.4049\/jimmunol.181.9.5948","article-title":"IL-23 promotes maintenance but not commitment to the Th17 lineage","volume":"181","author":"Stritesky","year":"2008","journal-title":"J. Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/bjd.19866","article-title":"Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)","volume":"185","author":"Thaci","year":"2021","journal-title":"Br. J. Dermatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"851246","DOI":"10.3389\/fphar.2022.851246","article-title":"Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS","volume":"13","author":"Tian","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1080\/14740338.2023.2223952","article-title":"Post-marketing safety concerns with upadacitinib: a disproportionality analysis of the FDA adverse event reporting system","volume":"22","author":"Wu","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"B47","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review","volume":"22","author":"Yang","year":"2021","journal-title":"Am. J. Clin. Dermatol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","article-title":"A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib","volume":"12","author":"Yin","year":"2022","journal-title":"Sci. Rep."},{"key":"B49","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B50","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/bcp.15535","article-title":"Toxicity signals associated with secukinumab: a pharmacovigilance study based on the United States Food and drug administration adverse event reporting system database","volume":"89","author":"Zheng","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1320458","DOI":"10.3389\/fphar.2023.1320458","article-title":"A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database","volume":"14","author":"Zou","year":"2023","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1420478\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T12:51:09Z","timestamp":1720615869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1420478\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":51,"alternative-id":["10.3389\/fphar.2024.1420478"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1420478","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,10]]},"article-number":"1420478"}}